No Data
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Neumora Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Watching Neumora Therapeutics; Shares See Volume To The Upside, Traders Circulate Unconfirmed Analyst Comments Saying "We Remain Buyers Into NMRA's MDD Data, Citing JNJ's Early Completion Of Phase III Aticaprant Study Efficacy And Safety Profile,...
10 Health Care Stocks With Whale Alerts In Today's Session
Positive Outlook on Neumora Therapeutics Driven by Navacaprant's Potential in MDD Treatment
Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Tourmaline Bio (TRML)